What’s New In Quality and Regulatory? (2026)
Originally presented Oct. 13, 2026
Overview
This webinar reviews key federal legislative and regulatory developments affecting clinical laboratories, including PAMA reimbursement reform, the Enhancing CLIA Act, the CLIA modernization RFI, termination of COVID-19 EUA authorities, and recent CLIA memo updates.
Presenters
Chelsea Conn, M.A., CQA(ASQ), MLS(ASCP)CM
Director of Regulatory Affairs
Department of Laboratory Medicine and Pathology
Mayo Clinic, Rochester, Minnesota
Jennifer Nosbisch, MBA
CLIA Compliance Program Manager
Revenue Compliance Office, Integrity and Compliance Office
Mayo Clinic, Rochester, Minnesota
Learning objectives
Upon completion of this activity, participants should be able to:
- Summarize the current status of PAMA and Medicare laboratory reimbursement reforms.
- Describe the proposed Enhancing CLIA Act and its potential impact on LDT oversight.
- Explain the purpose and major themes of the 2026 CLIA RFI.
- Discuss the implications of HHS terminating COVID-19 EUA declarations.
- Identify operational and compliance impacts arising from recent CLIA memo updates.
Intended audience
This webinar is appropriate for laboratory administrators and managers, safety coordinators, quality assurance and control staff, supervisors, and other laboratory personnel who are dedicated to safety, continuous quality, and process improvement.
Credit
The following types of credit are offered for this event:
ASCLS P.A.C.E.®
Mayo Clinic Laboratories is approved as a provider of continuing education programs in the Clinical Laboratory Sciences by the ASCLS P.A.C.E.® program. This program has been approved for a maximum of 0.5 P.A.C.E.® contact hour.
To obtain credit
To obtain credit:
- View the content.
- Complete the post-test and evaluation.
- Generate and print your certificate.
Level of instruction for this program is basic.
Credit expires October 13, 2028.
Faculty disclosure
Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.
Questions
Contact us: mcleducation@mayo.edu
